focus -WSS

focus

author：leisure time 2025-10-02 23:30:11 - browse：8

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： With clinical trial data readouts, here's how to spot spin

leisure time

WSS

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

What to do when lifesaving products contribute to climate change

As biotech industry slumps, bioscience job market is upside down

PBM reforms clear House panel

Why medical students are struggling with mental health

Why medical students are struggling with mental health

entertainment

focus

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

A daunting task: navigating dual Medicare, Medicaid eligibility

Jerome Adams on the need for new antivirals for Covid

Wegovy, Zepbound and weight loss drugs that preserve muscle

Dobbs anniversary: the lost opportunity of abortion as health care

Takeda, Janssen join wearable maker to measure scratching

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Duchenne breakthrough therapy leaves behind pioneering families

Diagnostic tests are hitting their mathematical limits

focus

Cigna, Humana reportedly in talks to merge

How to pay for weight loss drugs and save Medicare

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

ReNAgade cuts staff seven months after raising $300 million

30 years of 'Listening to Prozac'

Poor hospice wound care hurts patients and families

hotspot

leisure time

knowledge

Wikipedia